BiotechTube
Peptomyc

Peptomyc

Barcelona, Spain· Est.
peptomyc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40.8M

Overview

Peptomyc is a clinical-stage biotech developing a novel class of MYC inhibitors based on its proprietary Omomyc-derived mini-protein platform. Its lead asset, OMO-103, has demonstrated safety and early clinical activity in a Phase I trial, leading to the initiation of a Phase Ib trial in pancreatic cancer and a Phase II trial in osteosarcoma. The company is positioned as a trailblazer in targeting the historically 'undruggable' MYC transcription factor, with the potential to address a high unmet need across many cancer types.

Oncology

Technology Platform

Proprietary platform for designing cell-penetrating mini-proteins that directly inhibit the MYC transcription factor by disrupting its dimerization and DNA binding.

Funding History

3
Total raised:$40.8M
Series B$22M
Series A$16M
Seed$2.8M

Opportunities

The direct inhibition of MYC, a target implicated in ~70% of cancers, represents a massive and foundational market opportunity.
Success in pancreatic cancer, a setting with severe unmet need and poor survival, could lead to rapid adoption and serve as a proof-of-concept for expansion into numerous other MYC-driven malignancies.

Risk Factors

The primary risk is clinical: early efficacy signals may not hold in larger, controlled trials.
As the pioneer in direct MYC inhibition, the company bears the unique risk of validating a novel drug class, where unknown long-term toxicities could emerge.
Financial reliance on fundraising poses a continual risk to operations.

Competitive Landscape

Competition is indirect, focusing on modulating MYC expression or stability (e.g., BET inhibitors, KRAS inhibitors upstream) rather than direct inhibition. Other modalities like PROTACs are being explored for MYC but are earlier stage. Peptomyc's first-mover advantage with a clinically validated direct inhibitor is its key differentiator.

More companies in Small Molecule Drugs →More companies in Spain →